4591 M-リボミック 2019-05-14 15:00:00
2019年3月期第4四半期決算説明資料 [pdf]
1
4 0 25
0 1 23
▷ 6,3 /0/ R C Q G A 3
• 7 712 7 B Q
• F h Q
• Qu 5w
• M Qw
▷ UC d C R M w DeH
s w
▷ ad -) ST C M w DR C Q
I y w
▷ 3 7( t P D t s
031
.2
142
0. 9
3
B
B D
7
5 D E9 5
5 5 5
8G6 9
E 5 5
L 5 5 5
M 5 5 5
1 G 9 5
5 3 - 0 A P R2 R
4
4 9
4 9 4
1
7 5, -2 0
8
7 5
8
63
8
5
8
1 27
0. 9
3
1
RBM-007 FGF2 (AMD)
RBM-007 FGF2 AMED ( 8)
RBM-007 FGF2
RBM-004 NGF
RBM-003 Chymase 2
RBM-010 ADAMTS-5
RBM-006 Autotaxin
RBM-001 Midkine
1
RBM-101 IgG Fc
B
7 1 20 - / 8
,o
(u p.694 ynN
u p10. 2A F F A 3 I 0D 230 .CC F AN
u 10. c lg N
/ A 8D a p g
,u /64 vs N 4266/ 7 AA /. N
g R N lh le c N
u g TV
u Oci gN t
o
u Oci g r Pci gN t
u Pci g w ci gN t
)u ci g t
S u 5
12
o
t phle m RT Jn
T u
o
t c m l d sR J hci N
T u
t -0-376 Sy Tr R J y
0
o
t 5.3 T M Sy n RT T
18 8 A A 8 ..5 ,
o
t i aH hci S uSy n n RT
T
2 8 3A 9 8C 7 C8B 4 9 9 -9 :D ,
0
2 1
R 9 2- TB
G JM8 2 F B 7
6
9145 T -45 A
S 9 0 F G JM8 I B
7 6 7 B
ADE B 9
ADE~ 9 DC 9 B
9 7
( )
m
M C ul n S
rm
sF mG
i
c
5.0/ t F V H a V C eE Ha GD
2- N dE o
1 - 36A , 8:A : 86: 26 8 68
3 1
) ,7 1 2 ) 31/ ( VL G y GFA
▷ VM A ED F V A
A M c M
▷ M i A M A u A
▷ M a
s
+
n M M e
l t M
(l L ) L M A
2
▷ F RE 2
▷ 4P G G 1
) O
TGFβ2 V
FGF2 C
(
FGF2
P P TM
VEGF
FGF2
R E R
RE
RNG UYS
O
B 1B B 1 DB . A % C
BC 20 5) B B A B F B8 .C B 8F CB
5F8B CD B DE F 2 20 B C F 5C F I EF
5.
DC EECD 2 , D FCD
0 8 BF D
DC EECD
. %0 MK I QO
$ S
5
D ) 5)
2 7 E ) ,
.2 A C 18 8A D8 RP ON hc U M
$ 5F8 e aY ilk f d
1 ()( HI
HI 1 2 / S P P
S C M GB P M 3. v tw
S ci h :/10 d R u
C M GB d ce ig
SW
C M GB U V b
I
l o M A DO DM . .D .
Ulsprsm
6 MD F FM M 3 D F1 J G M . 2 F FG
nk V
6 MD F FM M 3 D F1 J G M . 3 B M C B
, 6 MD D M F M E . C 6
wc h a
y Tnr s gd
cfh d U d V
)
20 1 0 -/-() H 7
e Day 1 Day 7 Week 4 Month 2
T H R e
fh a twr
mtw
I M - B
1.12 0
1.12 0
1.12 0
mtw s
g i 3 , 72 0 Cy o
S v
▷ a dG 1. ( e R
09 BB 4 2 A B 2A49 1B 2 . 9 92 8F
▷ m G (
▷ cdG 2 8 8 42 2 B42AA 8 2
24 2 2 A 2B -A 9
24 A 2 2 A 2 2 B
A 2 B 2B
▷ m G A 9B lh
T aO TV gfk
o ainb
▷ s o1 o1 tb l
▷ - - -
▷ o G r
FGF2
FGF9 FGF2
FGF9
i 9 1 1
Fc l w h wa
0 6
▷ 1 6 0
▷ 6
6 ) 23 7 C C
% C
%
5
▷ e rw f B 1 55
▷ AR -, B 05 5 1 5 0 1 15 1 5 05 52
▷ dip tllb D O Mbo AT
-, p M m
▷ g -, ABhanSA
s
- 1 0
ut opi 09 D56 = 9 19 5= 19 011 a c
d b em kʼ lP nvM
)
. :B
2- 5= 9 0 B5 < 5 5=
B9
5= 9 : <: : <:
ryz
3/1 Rry S R d b eRgs
-
Angiotensin I proMMP-9
Angiotensin II MMP-9
3
TGF-β TGF-β
precursor
0 3
▷ 2
▷ 2
- 3 R
0
M
R
M
C
-
M B 0
4
B
2
03
1 2
0. 9
5 3
7 7
2/ 1 / - -() - 0
F
s Rl
s h
2/ 1 - 0
F
h C BAD
P 7 837 8 Nm hn t aI
h e 1/ O
0 29 h d
F
0 29 h 0628
2 -
-
V G G
E C) E C) O
E C)
T27 D
b b aI
mTw
lr hp - RT 7C C B7AF O 4 (
C B7AF
c Mc
y R O I b T o vO
t
3 5 T v
GN~n G ~n
40 3 0 7 eRT i
(
*
) a
(
427
( ) *
4 0 eD AR c 02764 14842735 / 74M ) F D MD
h (
o l k R
r R 9 10 p
: 5 yt a hg
GL 5 a m u hg
: 5 9 10 4J D HN LB N
GL 5
• yt sV o S o
: 5 • W o M k V
• c v S
• R a o
• yte
• e
7,5
• M i e
5 GA EF -ECCJD L L 2 B 3EJGD B k ~ e n
9 H ED Dn k ~ 7E n E G Hn 7 D GEDn k DDJ B 7 FEG e 9 10
v V 5 e® r n
n
)
ED .0 P 4- lfP
S VnaM iN
S VOR cna T Y kna
na e EGB L4 ) , 8 9 - , CA I (
1 1 .,1 FG HH G C H 2 29 FG HH G C H
a 7I L L > 3 GD
ax 6 M LD >
3763 1 4 O L B LDGB 1 >L
b 1 MD L R GLD 8021 IL F
1 GLD G
b S 8 33 8 3
gc h 8021 m ~ p f
nr
t f l b s
e N L 50 P 50 d U
e d i ovw ovw
IA GL $$ 5D D G ) 5D D G
5D L G - % D D G IA GL y U ( 5D D G
P LP %$ $
$
3
3
1
1 3
3
3
3
01 20 4